Response to Comments: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer

This response-to-comments document pertains to MolDX LCD DL38985 (renamed to 'MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer') and records the comment period (05/20/2021–07/03/2021), notice period start (05/19/2022), and effective date (07/03/2022). The document summarizes provider comments and administrative changes but does not itself specify clinical coverage, indication, frequency, or documentation requirements for testing; the underlying LCD should be consulted for clinical criteria.

"This document records that the comment period for LCD DL38985 ran 05/20/2021–07/03/2021, the notice period begins 05/19/2022, the LCD becomes effective 07/03/2022, and the LCD title was revised to ..."

Sign up to see full coverage criteria, indications, and limitations.